| Methods |
DESIGN: prospective, randomised, double blind, placebo‐controlled trial
RANDOMISATION: method of randomisation not described |
| Participants |
N = 50 (randomised and completed)
AGE: 1‐8 years (mean 5,2 years)
SEVERITY: allergic bronchial asthma with positive skin tests; desensitization performed without great benefit |
| Interventions |
DOSE: 1, 1,5 or 2 mg/d according to body weight
RUN‐IN: 0 weeks
TREATMENT: 12 weeks
ADDITIONAL MEDICATION: symptomatic anti‐asthmatic treatment with beta‐2 stimulants, theophylline or corticosteroids was continued and then gradually reduced until it was withdrawn or symptoms recurred |
| Outcomes |
overall assessment of efficacy by physician, total duration and frequency of asthmatic episodes per observation period, safety and side effects |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Described as randomised; other information not available |
| Allocation concealment? |
Unclear risk |
Information not available |
| Blinding?
All outcomes |
Unclear risk |
Information not available |
